LianBio
Close on Oct 19, 2026
- Market cap
- $6.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | $-0.22 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | During market hours | – | $-0.22 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 27, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 30, 2022 | During market hours | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Dec 9, 2021 | During market hours | – | – | – |
Press releases
Announcements LianBio filed with the SEC
LianBio Announces Completion of Strategic Review
Exit or restructuring costs · Listing notice · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LianBio Announces Departure of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LianBio Announces Departure of Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
Regulation FD disclosure · EX-99.1 to Form 8-K
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
Other events · EX-99.1 to Form 8-K
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LianBio Announces Topline Results from Phase 3 LIBRA Trial of
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EXPLORER-CN Topline Data Results and Mavacamten China Commercial Opportunity Call May 1, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Significant Commercial Leadership Experience Across Diverse and Relevant Therapeutic Areas, Including Global and China Launch Execution Select commercialization experience Cardiometabolic Oncology RespiratoryOphthalmology & Other 12 Inflammatory Disease
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LIANBIO May 12, 2022 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K